Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New glycogen phosphorylase inhibitors discovered at Yamanouchi

Sep. 29, 2004

Sertraline demonstrates potential in treating bulimia

Sep. 28, 2004

Patient recruitment starts in a phase I clinical trial with DAC:GRF

Sep. 28, 2004

Novel glucagon antagonists covered by Merck patent

Sep. 28, 2004

FDA grants priority review to investigational female testosterone patch

Sep. 27, 2004

Therapeutic benefits of SomatoKine in a child with Leprechaunism

Sep. 27, 2004

E.U. approves Xenical label change

Sep. 27, 2004

Pfizer researchers describe new cannabinoid CB1 antagonists

Sep. 27, 2004

Novel DPP-IV inhibitors and their use in type 2 diabetes claimed by Merck

Sep. 27, 2004

Extended Aranesp dosing approved by European Commission

Sep. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...